INOVIO PHARMACEUTICALS, INC. Increase (Decrease) in Derivative Liabilities
INOVIO PHARMACEUTICALS, INC. (INO) reported Increase (Decrease) in Derivative Liabilities of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2023-03-01
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for the quarter ending 2021-12-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for the quarter ending 2021-09-30 was $0.00.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for fiscal 2022 was $0.00.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for fiscal 2020 was $75.67M, a 4190.58% increase from fiscal 2019.
- INOVIO PHARMACEUTICALS, INC. increase (decrease) in derivative liabilities for fiscal 2019 was $1.76M.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | -$35.31M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | -$35.31M derived: sum of 3 quarters · filed 2023-03-01 | $62.45M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$35.31M derived: sum of 2 quarters · filed 2023-03-01 | $62.45M derived: sum of 3 quarters · filed 2023-03-01 | $75.67M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$35.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $62.45M derived: sum of 2 quarters · filed 2021-11-09 | $75.67M 10-Q · filed 2021-11-09 | $79.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $97.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $110.98M 10-Q · filed 2021-08-09 | $115.29M derived: sum of 3 quarters · filed 2022-03-01 | $112.74M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $13.22M 10-Q · filed 2021-05-10 | $17.54M derived: sum of 2 quarters · filed 2022-03-01 | $14.99M derived: sum of 3 quarters · filed 2022-03-01 | $14.99M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.76M derived: sum of 2 quarters · filed 2022-03-01 | $1.76M derived: sum of 3 quarters · filed 2022-03-01 | $1.76M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$2.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$2.55M derived: sum of 2 quarters · filed 2020-11-09 | -$2.55M 10-Q · filed 2020-11-09 | -$2.55M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |